Constitutional mismatch repair deficiency as a differential diagnosis of neurofibromatosis type 1: consensus suggestions for testing a child without malignancy by Suerink, Manon et al.
HAL Id: hal-02331880
https://hal.archives-ouvertes.fr/hal-02331880
Submitted on 24 Oct 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Constitutional mismatch repair deficiency as a
differential diagnosis of neurofibromatosis type 1:
consensus suggestions for testing a child without
malignancy
Manon Suerink, Tim Ripperger, Ludwine Messiaen, Fred Menko, Franck
Bourdeaut, Chrystelle Colas, Marjolijn Jongmans, Yael Goldberg, Maartje
Nielsen, Martine Muleris, et al.
To cite this version:
Manon Suerink, Tim Ripperger, Ludwine Messiaen, Fred Menko, Franck Bourdeaut, et al.. Consti-
tutional mismatch repair deficiency as a differential diagnosis of neurofibromatosis type 1: consensus
suggestions for testing a child without malignancy. Journal of Medical Genetics, BMJ Publishing
Group, 2019, 56 (2), pp.53-62. ￿10.1136/jmedgenet-2018-105664￿. ￿hal-02331880￿
1 
 
Constitutional mismatch repair deficiency as a differential diagnosis of neurofibromatosis type 1: 
consensus suggestions for testing a child without malignancy  
Manon Suerink1, Tim Ripperger2, Ludwine Messiaen3, Fred Menko4, Franck Bourdeaut5, Chrystelle 
Colas6,7, Marjolijn Jongmans8,9, Yael Goldberg10, Maartje Nielsen1, Martine Muleris7, Mariëtte van 
Kouwen11, Irene Slavc12, Christian Kratz13, Hans Vasen14, Laurence Brugiѐres15, Eric Legius16, Katharina 
Wimmer17* 
1. Department of Clinical Genetics, Leiden University Medical Centre, Leiden, the Netherlands 
2. Department of Human Genetics, Hannover Medical School, Hannover, Germany 
3. Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA. 
4. Family Cancer Clinic, Antoni van Leeuwenhoek Hospital and The Netherlands Cancer Institute, Amsterdam, The 
Netherlands 
5. Département d'Oncologie Pédiatrique et d'Adolescents Jeunes Adultes, Institut Curie, Paris, France 
6. Department of Genetics, Institut Curie, Paris Sciences Lettres Research University, Paris, France 
7. Sorbonne Universités, UPMC Univ Paris 06, INSERM, CNRS, Centre de Recherche Saint-Antoine (CRSA), F75012, 
Paris, France 
8. Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands 
9. Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands  
10. Recanati Genetics Institute, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel  
11. Department of Gastroenterology and Hepatology, Radboud University Medical Center Nijmegen, Nijmegen, The 
Netherlands 
12. Department of Pediatrics, Medical University of Vienna, Vienna, Austria. 
13. Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany 
14. Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands 
15. Children and Adolescent Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France 
16. Department of Human Genetics, University Hospital Leuven and KU Leuven, Leuven, Belgium 
17. Division of Human Genetics, Medical University Innsbruck, Innsbruck, Austria 
*corresponding author: Katharina Wimmer, PhD, Division of Human Genetics, Medical University Innsbruck, Peter-Mayr-
Straße 1, 6020 Innsbruck, Austria. Tel.: +43512 9003 70513; fax: +43512 9003 73510; e-mail: katharina.wimmer@i-
med.ac.at 
Word count: 4790 
  
2 
 
 
Abstract 
Constitutional mismatch repair deficiency (CMMRD) is a rare, autosomal recessively inherited cancer 
predisposition syndrome caused by biallelic germline mutations in one of four mismatch repair 
genes (MLH1, MSH2, MSH6, and PMS2). In addition to a very high tumour risk, the CMMRD 
phenotype is often characterized by the presence of signs reminiscent of neurofibromatosis type 1 
(NF1), mainly in the form of multiple café-au-lait macules (CALMs). These, as well as other non-
malignant features, are important diagnostic signs of CMMRD in a cancer patient. Conversely, 
CMMRD is also a potential differential diagnosis in an otherwise healthy child with signs reminiscent 
of NF1/Legius syndrome without a detectable underlying NF1/SPRED1 germline mutation, as 
exemplified by a recently described case of a six-year-old girl with multiple CALMs, the offspring of 
consanguineous parents without signs of NF1, who was diagnosed with CMMRD. The European 
consortium Care for CMMRD (C4CMMRD) has now reviewed the expected benefits as well as the 
potential harm of CMMRD counselling and testing in this setting, for both the index patient and 
his/her at-risk relatives. Assuming that, in the absence of additional indicative features, CMMRD is 
rare in these patients, existing CMMRD diagnostic criteria for cancer patients were adapted to 
provide a consensus guideline on CMMRD testing in a child without a malignancy. Counselling and 
testing strategies that serve to minimize the potential harm of testing are discussed. Evaluation of 
this guideline by careful monitoring of children and by data sharing among physicians is 
recommended. 
Keywords Genetic screening/counselling, Clinical genetics, Paediatric oncology 
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INTRODUCTION 
Constitutional mismatch repair deficiency (CMMRD, MIM #276300) is a rare, autosomal-recessively 
inherited cancer predisposition syndrome caused by biallelic germline mutations in one of four 
mismatch repair (MMR) genes (MLH1, MIM *120436; MSH2, MIM *609309; MSH6, MIM *600678; 
PMS2, MIM *600259). CMMRD was first described in 1999 in children of consanguineous parents in 
Lynch syndrome families.1 2 These children, carrying homozygous MLH1 mutations, developed early 
onset tumours and presented with a phenotype reminiscent of neurofibromatosis type 1 (NF1) 
mainly in the form of multiple café-au-lait macules (CALMs). Since these first reports, well over 200 
cancer patients with CMMRD have been described. Through these reports and establishment of 
initiatives, such as the European consortium ‘Care for CMMRD’ (C4CMMRD), the international 
biallelic mismatch repair deficiency (BMMRD) consortium and the European Reference Network for 
rare genetic tumour risk syndromes (ERN-GENTURIS), awareness of CMMRD and our understanding 
of the phenotype, the pathophysiological mechanisms of tumour development and potential 
management options have increased substantially.3-8 
Individuals with CMMRD are prone to develop a broad spectrum of tumours. The most common are 
T-cell non-Hodgkin lymphomas, high-grade gliomas, and colorectal cancers or (advanced) colorectal 
adenomas, but also a number of other malignancies are associated with CMMRD.7 9-12 Although 
ascertainment bias cannot be excluded, cancer risks appear to be extremely high, as almost all 
reported patients are diagnosed with a malignancy and approximately 80% of patients develop their 
first malignancy before the age of 18 years (median age of onset 10 years).7 10 11 13-16 However, 
attenuated forms of CMMRD with a higher age of tumour onset have also been reported, which are 
presumably caused by hypomorphic mutations (with reduced penetrance) in at least one allele.17-19 
 
Already from the first reports, it became clear that the CMMRD phenotype overlaps with that of NF1 
and prior to the onset of CMMRD-associated malignancies, it may be indistinguishable from this 
condition. Multiple (>5) CALM (> 0.5cm in diameter) are usually the first diagnostic sign of NF1.20 In 
NF1, CALMs generally already appear in the first year of life, followed by skinfold freckling which is 
present in most children by school age. Neurofibromas usually develop after puberty and in early 
adulthood.20 In the past, the majority of NF1 diagnoses were based on clinical criteria from the 
National Institutes of Health (NIH).21 However, in young children who have a de novo NF1 mutation 
(accounting for almost 50% of NF1 index cases) the NIH criteria are often not fulfilled. Therefore, 
many NF1 clinics and paediatricians aim for early diagnosis in children through genetic testing, made 
possible by the improved sensitivity of NF1 mutation analysis protocols.22 23  
The most important differential diagnoses of NF1 in children with multiple CALMs are mosaic NF1 
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and Legius syndrome.24 25 From the mutation detection rates in familial and sporadic individuals 
fulfilling NF1 diagnostic criteria (95% vs. 85%26) it can be deduced that at least 10% of sporadic NF1 
cases have mosaic NF1 caused by post-zygotic NF1 mutations that are undetectable in blood 
lymphocytes. Mosaic NF1 may present as segmental NF1, with NF1 features confined to one part of 
the body or as a more generalized form that may be indistinguishable from (mild forms) of NF1 due 
to a germline mutation.25 Legius syndrome (MIM #611431), characterized by CALMs and freckling 
but absence of other diagnostic NF1 features, is caused by germline mutations in SPRED1 (MIM 
*609291).24 About 2.4% of sporadic patients with multiple (>5) CALMs with or without freckling, and 
in whom no NF1 mutation can be identified, have Legius syndrome.26 Other potential differential 
diagnoses of NF1 include Noonan syndrome, Noonan syndrome with multiple lentigines (previously 
referred to as LEOPARD syndrome), neurofibromatosis type 2 (NF2), Piebald trait and McCune-
Albright syndrome.27 However, the latter syndromes are often accompanied by other clinical 
features that can help in differentiating between syndromes.   
Since CMMRD patients with >5 CALMs and other NF1 signs have been described, it is unsurprising 
that CMMRD patients occasionally receive an initial clinical diagnosis of NF1 before receiving the 
correct diagnosis.1 2 28 29 Although not all CMMRD patients have sufficient CALMs to meet the NF1 
diagnostic criterion of >5 CALMs and some reports emphasize that CALMs in CMMRD patients often 
differ from the typical uniformly pigmented and smooth-bordered CALMs associated with NF1,30-33 
the majority of CMMRD patients have some hyperpigmented macules reminiscent of NF1-associated 
CALMs.34 Indeed, Durno and colleagues reported CALMs/hyperpigmented macules in 33 of 34 (97%) 
CMMRD patients described by the international BMMRD consortium,10 and CALMs are present in at 
least 57 of 76 (75%) patients registered in the C4CMMRD consortium database. The number of 
CALMs (diameter >1 cm) is known for 35 cases in the latter database, and more than five CALMs >1 
cm were found in 26 of 35 (75%) patients (at ages ranging from 0.9-21 years) suggesting that about 
half of all CMMRD patients fulfil at least one NIH criterion of NF1 (i.e. >5 CALMs). 
Awareness that CALMs and occasionally other NF1 signs may be present in a child with CMMRD prior 
to tumour onset leads to the conclusion that CMMRD is a legitimate differential diagnosis in healthy 
children with CALMs (with or without other clinical signs of NF1/Legius syndrome) when no 
causative NF1 or SPRED1 mutation is identified, and no signs of NF1 are found in the parents. 
Although we can reasonably assume that CMMRD is rare in these patients if the parents are 
unrelated (see below Estimated frequency of CMMRD as a differential diagnosis to NF1), a six-year-
old child of consanguineous parents with >5 CALMs and no cancer was recently diagnosed with 
CMMRD.28 In this situation, a diagnosis of CMMRD may provide an opportunity for cancer 
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surveillance of a highly penetrant childhood cancer syndrome prior to onset of the first malignancy. 
It will also allow predictive genetic testing and surveillance in relatives at risk for both CMMRD and 
Lynch syndrome and may impact family planning. However, it is also important to consider the 
potential harm associated with CMMRD counselling and testing in this setting, and any harm should 
be outweighed by expected benefits for both the index patient and his/her at-risk relatives. 
Therefore, physicians and geneticists have begun to discuss if and when to counsel and test for 
CMMRD in suspected NF1 patients.35  
The C4CMMRD consortium, an interdisciplinary team of international experts in the field, has 
formulated and published diagnostic criteria for the clinical suspicion of CMMRD in cancer patients,7 
in addition to surveillance guidelines.6 At the most recent workshop in Brussels (26th of September 
2017), the issue of when to test children without malignancy for CMMRD was addressed. The 
outcome of that discussion will be presented here. We propose the adaptation of existing diagnostic 
criteria to serve as a guideline as to when to consider CMMRD counselling and testing as differential 
diagnosis to NF1 in healthy individuals.  
ESTIMATED FREQUENCY OF CMMRD AS A DIFFERENTIAL DIAGNOSIS OF NF1  
The frequency of CMMRD in children suspected to have NF1 or Legius syndrome, but without a 
causative NF1 or SPRED1 mutation and no overt malignancy, is currently unknown. Since knowledge 
of disease frequency would help in weighing the possible benefits and harm associated with 
counselling and genetic testing, in the following section we attempt to roughly estimate the 
frequency. 
The incidence of CMMRD in the general population depends on the carrier frequency of MMR 
mutations. The most recent empiric estimation, based on a large North American/Australian registry, 
calculated carrier frequencies of 1 in 1,946 for MLH1, 1 in 2,841 for MSH2, 1 in 758 for MSH6, and 1 
in 714 for PMS2 mutations.36 Based on these frequencies, CMMRD incidence was calculated to be 
about 1:1,000,000 children of unrelated parents (Figure 1). The incidence will be substantially higher 
in populations with founder MMR mutations and in children of consanguineous parents.15 37 38  
NF1 is much more common, with an estimated incidence of around 1:2,000-1:3,000.39-41 Almost half 
of patients with NF1 are de novo cases.39 To estimate the frequency of suspected NF1 or Legius 
syndrome patients without an NF1 or SPRED1 mutation who are actually affected by CMMRD, we 
took a number of factors into account. In a study using highly sensitive and comprehensive mutation 
analysis protocols, with mutation detection rates of 96% in familial NF1 patients, NF1/SPRED1 
mutations were identified in 56.4% (764/1354; 751 NF1 and 13 SPRED1 mutations) of suspected 
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sporadic NF1 patients with >5 CALMs.26 Therefore, based on the incidence of de novo NF1 of 1:6,000 
new-borns and an NF1/SPRED1 mutation detection rate of 56.4% in patients with >5 CALMs with or 
without other signs of NF1, we assume that there are 129 patients with >5 CALMs and no 
NF1/SPRED1 mutation in a population of 1 million individuals (Figure 1). Combining this estimate 
with the estimated frequency of CMMRD, and assuming that half of all CMMRD patients present as 
suspected NF1 patients prior to cancer development, we obtain a figure of one CMMRD patient 
among 258 suspected NF1 children without an NF1/SPRED1 mutation (i.e. ~0.4%) (Figure 1). Given 
this low estimated frequency, a priori chances of diagnosing CMMRD in this group are low.  
POTENTIAL BENEFITS AND HARM OF CMMRD COUNSELLING AND TESTING IN A ‘HEALTHY’ CHILD 
Several factors need to be taken into account when considering CMMRD diagnostics in a child 
without a (personal history of) malignancy (Table 1).  
Table 1 Overview of the potential benefits and harms of CMMRD counselling and testing in a 
suspected sporadic NF1/Legius syndrome child without malignancy and negative outcome of NF1/ 
SPRED1 germline mutation analysis. 
Potential benefits Potential harms 
 Opportunity to begin surveillance before 
cancer development  
 Parents can be informed of the 
recurrence risk in a sibling/future child 
 Lynch syndrome can be diagnosed in  
family members and surveillance 
initiated 
 Risk of diagnosing Lynch syndrome in a 
minor  
 Risks associated with intensive 
surveillance while efficacy has not yet 
been evaluated in a large cohort and 
attenuated forms of CMMRD exist 
 Risk of identifying a VUS, resulting in 
management dilemmas and potentially 
inducing anxiety 
Abbreviations: CMMRD, constitutional mismatch repair deficiency. VUS, variant of unknown 
significance. 
Benefits and their limitations 
i) One of the most important benefits of an early CMMRD diagnosis is the possibility to begin 
surveillance before cancer development and, consequently, potentially detect cancer at an early 
stage with better treatment options. With regards to colorectal cancer risk, there is even the 
opportunity to prevent cancer by removal of intestinal polyps prior to malignant transformation, and 
existing recommendations for CMMRD surveillance provide clinicians with guidance regarding 
screening programs.3 5 6 All available guidelines recommend brain MRI, colonoscopies and video 
capsule endoscopy (VCE) from a young age, as well as gynaecological and urinary tract analysis from 
age 10 to 20 years. In addition, whole body MRI5 and preventive measures such as aspirin intake 
and/or vaccination with neoantigens42 43 are possible modalities that may have a role in CMMRD 
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management. Preliminary analyses in a small series of patients showed promising results for 
surveillance measures.44 Nevertheless, all recommended programs are intensive and burdensome 
and evaluation of the outcome of surveillance protocols in larger studies is yet to be published. 
Furthermore, when CMMRD is diagnosed in a predictive setting with regard to cancer development, 
it should be kept in mind that attenuated forms of CMMRD show tumour onset only by the end of 
the second or in the third decade of life, 17-19 45 and that no evaluated models are available to 
accurately estimate penetrance of novel MMR mutations or new combinations of mutations. Hence, 
it is currently unclear whether a less stringent surveillance program might be sufficient for a 
subgroup of patients. Despite these reservations, as sufficient evidence points to an overall high 
cancer risk, the application of intensive, carefully considered screening recommendations to 
individuals proven to have CMMRD is justified. 
ii) Another advantage of early diagnosis is the possibility to counsel parents regarding the 25% 
probability that siblings and subsequent children will also be affected, and to discuss the option of 
prenatal or preimplantation genetic diagnostics while parents are still in the process of family 
planning. Once again however, informed decision making is complicated by the fact that current 
estimates of cancer risk are subject to ascertainment bias and individual cancer risks are difficult to 
predict. 
Potential harms 
i) Following genetic counselling for CMMRD as a differential diagnosis, parents and children 
may experience anxiety during genetic testing until the diagnosis is largely excluded. Depending on 
the diagnostic strategy and performance of the laboratory, this may take several weeks or even 
months. Moreover, the testing strategy chosen by the laboratory will impact the predictive value of 
a negative test result (i.e. the residual risk in the case of a negative test, see Testing strategy). This 
may impact on any remaining anxiety after receiving a negative result. The level of anxiety may also 
differ depending on the personality and the available coping strategies of the patients/parents and 
the attitudes of the physicians involved.  
ii) Test results definitely confirming or refuting CMMRD will be helpful in the management of 
the patient and his/her family. However, inconclusive test results will pose a challenge for all parties 
involved. The most important source of inconclusive results will be variants of unknown significance 
(VUS) in the MMR genes. Although identification of a VUS is an inherent risk of genetic diagnostics, it 
is important to minimize the number of VUS and the dilemma with regard to diagnosis and 
appropriate management of the patient that comes along with it. Therefore, laboratories performing 
CMMRD analysis in a predictive setting should be prepared to take any measure necessary to reach a 
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less ambiguous classification of a VUS (C3) as either a (likely) pathogenic (C4/C5) mutation or a 
(likely) benign (C1/C2) variant.46 Tests assessing hallmarks of MMR deficiency in vivo or the effect of 
the mutation(s) on mismatch repair protein function in vitro will become important in these 
situations (see Testing strategy). 
iii) According to Win et al.,36 in the general population one in 279 children tested will be 
heterozygous for an MMR gene mutation. Particularly in the case of a clearly pathogenic MLH1 or 
MSH2 mutation, this results is the unintentional diagnosis of Lynch syndrome in a minor. Lynch 
syndrome mainly predisposes to adult-onset colorectal cancer and/or endometrial cancer and 
surveillance only begins around age 20-25.47 48 Thus the lack of clinical consequences in children, 
combined with their right not-to-know, and potential harm due to anxiety and other issues (e.g., 
potential difficulty in acquiring insurance) highlight that a diagnosis of Lynch syndrome is 
undesirable in a minor.49 Further considerations on this topic can be found in Bruwer et al. who 
offered predictive CMMRD testing to children of parents both carrying familial MLH1 mutations.50 
The situation is more complex for MSH6 and even more so for PMS2. Heterozygous mutations in 
these genes have a 2-4 times higher prevalence,36 but  a substantially lower penetrance than MLH1 
and MSH2 mutations.19 51 52 Hence, in an individual lacking a personal or family history of Lynch 
syndrome-associated cancer, it is uncertain whether the mutation-associated cancer risk is sufficient 
to diagnose an individual with a cancer predisposition syndrome that warrants intensive cancer 
surveillance. This concern also raises the question of whether identifying a mutation in an individual 
without family history for Lynch syndrome justifies predictive genetic testing in parents and other 
adult at-risk relatives.  
LIMITING POTENTIAL HARM ASSOCIATED WITH CMMRD COUNSELLING AND TESTING IN A CHILD 
WITHOUT A MALIGNANCY 
Assuming that only a small minority (~0.4%) of all NF1/SPRED1 mutation-negative children from non-
related parents will actually have CMMRD syndrome, it would be desirable to reduce the number of 
individuals/families with whom the possibility of CMMRD needs to be discussed. Therefore, 
strategies to pre-select children with a high probability of having CMMRD are discussed in the 
following section. 
Testing prerequisites 
Three prerequisites for considering testing for CMMRD as a differential diagnosis of NF1/Legius 
syndrome are defined in Table 2: (i) the presence of at least one NF1 diagnostic criterion including 
multiple hyperpigmented skin patches reminiscent of CALMs. The most prevalent NF1 sign present 
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in a CMMRD patient is hyperpigmented skin patches reminiscent of NF1-associated CALMs and 
freckling. Other diagnostic NF1 features such as neurofibromas, Lisch nodules, tibial pseudarthrosis 
or optic pathway glioma have so far only been seen in CMMRD patients who also show CALMs.1 2 15 53 
54 This suggests that CMMRD syndrome is a highly unlikely diagnosis in individuals with only isolated 
non-pigmentary NF1 features. (ii) NF1/SPRED1 testing was performed using highly sensitive, 
comprehensive mutation analysis protocols. The likelihood of identifying CMMRD is of course 
correlated with the sensitivity of NF1/SPRED1 mutation analysis performed (further discussed in 
Testing strategies). (iii) the absence of any signs of NF1 in either parent. If a parent shows any NF1 
signs, even very subtle, an undetected NF1/SPRED1 mutation, which might even be present in a 
mosaic status in the mildly affected parent, is probably more likely. It is strongly recommended that 
both parents undergo a full clinical exam for presence of any (mild) features of NF1, and for this 
purpose a consultation with an ophthalmologist and dermatologist can be considered. 
It was decided not to include an age limit in the prerequisites for testing, as in CMMRD a wide 
variability has been observed in the age of cancer diagnosis.11 45 52 However, when evaluating a 
patient who meets the prerequisites it should be kept in mind that the vast majority (around 80%)10 
11 13-16 of CMMRD patients will have developed a malignancy or intestinal adenomas by the age of 
eighteen. Hence, absence of a (pre-)malignancy in an older individual decreases the probability of 
CMMRD substantially.  
Pre-selection strategies 
The presence in a child of one or more additional features suggestive of CMMRD substantially 
increases the likelihood of this differential diagnosis. The European C4CMMRD consortium has 
previously defined diagnostic criteria based on features that raise suspicion of CMMRD in a cancer 
patient.7 By and large, these features could also be used to select children without cancer who have 
an increased probability of having CMMRD. Therefore, the list of additional features provided in 
table 2 largely overlaps with the previously defined diagnostic criteria for CMMRD in a cancer 
patient (for further details see 7).  
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Table 2 Selection strategy for CMMRD counselling and testing in a suspected NF1/Legius 
syndrome child without malignancy and negative outcome of NF1/ SPRED1 germline 
mutation analysis.  
  
Prerequisites  
 Suspicion of NF1 due to the presence of at least one diagnostic NF1 feature1, 
including at least two hyperpigmented skin patches reminiscent of CALMs 
 No NF1 and SPRED1 germline mutations detected using comprehensive and highly 
sensitive mutation analysis protocols2 
 Absence of NF1 signs in both parents  
Additional features, at least one is required 
In the family 
 Consanguineous parents 
 Genetic diagnosis of Lynch syndrome in one or both of the parental families 
 Sibling with signs of NF1 
 A (deceased) sibling3 with any type of childhood malignancy 
 One of the following carcinomas from the Lynch syndrome spectrum4: colorectal 
cancer, endometrial cancer, ovarian cancer, gastric cancer, small bowel cancer, 
cancer of the bile duct or gall bladder, pancreatic cancer or urothelial cancer before 
the age of 60 in first-degree or second-degree relative  
In the patient 
 Atypical CALMs (irregular borders and/or pigmentation) 
 Hypopigmented skin patches 
 One or more pilomatricoma(s) in the patient 
 Agenesis of the corpus callosum  
 Non-therapy-induced cavernoma 
 Multiple developmental vascular abnormalities (DVA; also known as cerebral venous 
angiomas) in separate regions of the brain 
Abbreviations: NF1, neurofibromatosis type 1. CALMs, café-au-lait macules.  
1Neurofibromatosis conference statement.(21)  2See testing strategy. 3This can be expanded to 2nd 
and 3rd degree relatives in populations with a high prevalence of founder mutations. 4Møller et al. 
2017 (47)  
A feature listed in the original table in 7 was ‘deficiency/reduced levels of IgG2/4 and/or IgA’. As a 
recent study on a cohort of 15 consecutive, unrelated patients was unable to show uniform or 
specific patterns of laboratory immunological abnormalities,55 we did not include this rather 
unspecific feature in table 2. 
Two features increasing the likelihood of having CMMRD and not listed in the original table by 
Wimmer et al.7  were added to the current table. The first one is a sibling with signs of NF1, in the 
absence of any NF1 signs in both parents when gonadal NF1/SPRED1 mosaicism in a parent has 
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largely been excluded by mutation analysis in the children. The second is the presence of multiple 
developmental vascular abnormalities (DVA; also known as cerebral venous angiomas) in separate 
regions of the brain, which were present in 10/10 patients described by Shiran et al.,56 who 
suggested this feature as additional non-neoplastic sign indicating CMMRD in a cancer patient.  
Furthermore, a number of CMMRD patients have been reported to have atypical CALMs with 
irregular borders and different degrees of pigmentation.30-34 Therefore, atypical macules that might 
be differentiated from typical NF1-associated macules by an experienced clinician/geneticist (see 
also Counselling strategy and setting), are suggestive of a differential diagnosis such as CMMRD.30-34 
Hence, presence of atypical CALMs is also included as an additional feature in Table 2. 
Some CMMRD-associated features included in Table 2 (e.g. brain anomalies) will not be detected by 
routine clinical examination of a suspected NF1 patient. Since the prevalence and specificity of these 
features in CMMRD patients is not well studied, we do not advocate testing for these features unless 
clinically indicated.  
A thorough family history will help in uncovering family members with Lynch syndrome-associated 
cancers (Table 2).  When a Lynch syndrome-associated cancer is present it may be worthwhile, 
where possible, to analyse the tumour for signs of mismatch repair deficiency.  
A thorough assessment of the family history should include also questions regarding consanguinity 
of the parents. The risk of having CMMRD based on the allele frequencies of MMR gene mutations36 
in for example a child of first cousins is ~1/8,849 (using the equation [pifI+pi
2(1-fI)]+[pjfI +pj
2(1-
fI)]+[pkfI +pk
2(1-fI)]+[plfI+pl
2(1-fI)] where pi, pj, pk and pl are the allele frequencies of MLH1, MSH2, 
MSH6 and PMS2 mutations, respectively, and the consanguinity coefficient fI for first cousins = 
1/16)57 which is about 110-times higher than for a child with unrelated parents.  
Counselling strategy and setting 
Since NF1 is a relatively common and often easily recognizable syndrome for which clear 
management guidelines exist, many paediatricians order molecular analysis of the NF1 gene directly 
without involving a clinical genetics specialist. Counselling and management are more challenging 
for the much rarer and highly penetrant cancer predisposition syndrome CMMRD. We therefore 
advocate that predictive (with respect to malignancy) CMMRD testing should be ordered by a 
physician trained in clinical cancer genetics in a centre with specific expertise in NF1 and related 
disorders in a multi-disciplinary setting.  
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As mentioned above, we suggest that CMMRD does not need to be discussed in all suspected NF1 
cases without an identified NF1/SPRED1 mutation. Following an interdisciplinary discussion and the 
decision that counselling for CMMRD is indicated in a child without a malignancy, parents and their 
affected child, depending on his/her age, should be counselled by an experienced geneticist. To be 
able to make an informed decision on whether they want their child to be tested, parents should be 
made aware of the potential benefits, with their limitations, and of the various possible outcomes of 
genetic testing. Nevertheless, considering the low probability of a CMMRD diagnosis, this 
information should be provided in a way that minimizes risk of inducing a disproportionately high 
level of anxiety. If parents express the need for psychological support or more information on 
surveillance protocols or cancer treatment options, consultation with a psycho-oncologist or 
paediatric oncologist should be offered.  
Specifically trained clinical geneticists/clinicians may be able to differentiate between typical NF1-
associated CALMs and the atypical pigmentations sometimes seen in CMMRD patients.30-34 
Furthermore, he/she can decide whether another syndrome (e.g., Noonan syndrome, Noonan 
syndrome with multiple lentigines, NF2, Piebald trait and McCune-Albright syndrome) within the 
differential diagnosis of children with CALMs is more likely and should be addressed by genetic 
testing prior to CMMRD testing. Lastly, we advise that any centre ordering CMMRD diagnostics is 
able to facilitate the surveillance program, either in-house or in cooperating centres within 
reasonable travelling distance.  
Testing strategy 
A prerequisite for considering CMMRD counselling and testing as a differential diagnosis in patients 
suspect for NF1/Legius syndrome is the exclusion of the latter diagnoses with high certainty by 
absence of germline NF1/SPRED1 mutations using highly sensitive mutation analyses. The NF1 gene 
is large and has a highly diverse mutational spectrum, with private mutations (i.e. not reported in 
any other patient) identified in a significant percentage of patients (~25%; LM, personal 
communication). Furthermore, the NF1 mutation spectrum also includes a large proportion of 
unusual splice mutations that either completely elude genomic DNA (gDNA)-based mutation analysis 
protocols (e.g. deep intronic mutations are found in 2.5-3% of all NF1 patients) or defy ready 
classification as (likely) pathogenic mutations without additional transcript analysis (approximately 
20% of patients have a splice mutation NOT affecting the AG/GT dinucleotides, but affect coding 
nucleotides, nucleotides flanking the exons but further up/downstream of the AG/GT dinucleotides 
or reside very deep into the introns).22 58 59 This complicates the classification of novel mutations, 
especially in the case of silent, missense, and intronic variants.60 Currently, only comprehensive 
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mutation analysis protocols that include NF1 transcript analysis as a primary or complementary 
assay, such as direct cDNA sequencing,23 will achieve sufficient sensitivity to exclude a germline 
mutation with a 96% certainty. 26 Genomic DNA-based mutation analysis methods can achieve high 
SPRED1 mutation detection rates (RNA-based mutation analysis performed in >900 patients has not 
yet identified a SPRED1 splice mutation that escaped detection in gDNA; LM, unpublished data).  
Segmental or mosaic NF1 due to a post-zygotic NF1 mutation is the most likely differential diagnosis 
in a child with CALMs, with or without other NF1 signs, and a negative germline NF1/SPRED1 
mutation analysis. Confirming mosaic NF1 however requires identification of the same post-zygotic 
mutation in multiple melanocyte or Schwann cell cultures from biopsied CALMs and neurofibromas 
respectively.61 These labour intensive analyses require specific expertise and therefore are offered 
only by very few specialized laboratories worldwide. Furthermore, they require invasive procedures. 
Taken together, this can justify omitting these analyses in children to evaluate mosaic/segmental 
NF1 prior to CMMRD testing. 
In principle, two CMMRD testing strategies can be pursued. The first strategy is direct mutational 
testing of the MMR genes. The second strategy involves a pre-assay which tests for hallmarks of 
CMMRD, followed by mutational testing if positive. When opting for direct mutational testing it 
should be kept in mind that mutation analysis of PMS2, the most commonly mutated gene in 
CMMRD, is challenging due to the presence of pseudogenes.62-65 Therefore, appropriate methods 
should be applied to circumvent potential pitfalls of PMS2 mutation analysis.66-72 
An argument in favour of direct mutation analysis using gDNA-based gene panel diagnostics would 
be that other genes that may mimic the NF1 phenotype (see Introduction) can be analysed 
simultaneously. However, testing a larger number of genes inevitably increases the likelihood of 
identifying VUSes. Therefore, we advocate a stepwise approach, ruling out other possible differential 
diagnoses prior to CMMRD testing.  
If a VUS is identified in one of the MMR genes, additional analyses should be performed to assist 
with the interpretation of the variant, such as ex vivo functional assays of the mutated gene73-79 
and/or assays that determine the presence of MMRD in non-neoplastic tissue of the patient. The 
latter assays could also be used as pre-assays before or in parallel with mutation analysis. This 
second strategy reduces the risk of VUS identification by providing functional evidence for or against 
CMMRD, and at the same time increases diagnostic sensitivity by applying two complementary 
methods.  
Microsatellite instability (MSI), defined as a change in the number of mononucleotide or 
dinucleotide repeats and detectable by alterations in microsatellite fragment length,80 is a well-
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established hallmark of somatic MMRD and is frequently assessed in cancer tissues during testing for 
Lynch syndrome. MSI is not restricted to neoplastic cells in patients with CMMRD and assays have 
been developed to detect low levels of MSI in leucocyte DNA of these patients.81 Although highly 
sensitive and specific in patients with biallelic PMS2, MLH1 and MSH2 mutations, in patients with 
biallelic MSH6 mutations, the currently available germline microsatellite instability (gMSI) assays 
regularly yield normal results. This limitation renders this gMSI assay unsuitable for pre-test 
selection. However this simple, fast and inexpensive assay can increase diagnostic sensitivity and 
accuracy by confirming the pathogenicity of PMS2, MLH1 and MSH2 VUS.28 In the near future more 
sensitive, simple and reliable gMSI assays may become available, which could potentially be used for 
pre-test selection. Recently, a highly sensitive and reliable method for the detection of low levels of 
MSI was developed, with potential applications in the analysis of MSI in non-neoplastic tissue of 
CMMRD patients.82 Another assay, which tests for MSI in EBV-immortalised lymphocytes and in 
parallel for cell tolerance to methylating agents (another functional consequence of CMMRD), has 
recently been specifically developed for CMMRD diagnosis.83 As this assay is both highly sensitive 
and specific it may allow a diagnosis of CMMRD to be definitively confirmed or refuted in cases 
where mutation analysis and other assays are inconclusive (e.g. when only one MMR gene mutation 
or a homozygous MMR gene VUS has been identified).83 84 However, the assay is lengthy, labour 
intensive and requires expertise, making it ill-suited as a pre-test. Immunohistochemistry (IHC) to 
detect loss of expression of one or more MMR protein(s) in non-neoplastic tissue, such as small skin 
biopsies, has also been proposed as a diagnostic assay for CMMRD.10 13 However, as taking a skin 
biopsy is an invasive procedure that can be unpleasant for a young child, IHC should be avoided as a 
pre-test. Furthermore, IHC may also be insensitive if antigenic but non-functional mutations are 
present.84-86 
Taken together, reliable diagnostics of CMMRD may at times be challenging. Choosing an 
appropriate testing strategy may depend on the facilities that are most readily available in the 
centre. Hopefully, more assays will become available that may facilitate simple and reliable selective 
pre-testing for CMMRD.  
 
CONCLUDING REMARKS 
We discussed here the potential benefits and harm (Table 1) associated with CMMRD counselling 
and testing in children suspected to have sporadic NF1 but without a malignancy and lacking an NF1 
or SPRED1 germline mutation. After carefully considering all available literature and our own 
experiences, we arrived at recommendations as to when to counsel and offer CMMRD testing, which 
are summarized in Table 2. We also note that uncertainties exist regarding the incidence of CMMRD 
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and the prevalence of CMMRD-associated features both in the general population and in unselected 
CMMRD patients. Clearly, more data are needed to further support our recommendations, 
particularly since published CMMRD cases may be biased towards a more severe phenotype. We 
strongly recommend that the clinical course of all CMMRD patients who are identified before cancer 
development is meticulously recorded and submitted to a database. Overall, we believe that with 
the application of the suggested counselling and testing prerequisites an acceptable balance can be 
achieved between adequate testing of patients at risk of CMMRD, while avoiding exposing an 
unnecessarily large number of children and families to any harm that might ensue from counselling 
and genetic testing for CMMRD. 
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